{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:18:03Z","timestamp":1790295483785,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.leukres.2025.107732","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:56:34Z","timestamp":1749156994000},"page":"107732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis"],"prefix":"10.1016","volume":"155","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3361-3981","authenticated-orcid":false,"given":"Moshe","family":"Talpaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langmuir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Lamothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.leukres.2025.107732_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.107732_bib2","first-page":"121","article-title":"Myelofibrosis: clinicopathologic features, prognosis, and management","volume":"16","author":"Sullivan","year":"2018","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.leukres.2025.107732_bib3","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107732_bib4","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.leukres.2025.107732_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2025.107732_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107732_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.leukres.2025.107732_bib8","unstructured":"Jakafi (ruxolitinib) [prescribing information], Incyte Corporation, Wilmington, DE, 2023."},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2025.107732_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2025.107732_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107732_bib14","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00277-020-04002-9","article-title":"Management of myelofibrosis after ruxolitinib failure","volume":"99","author":"Harrison","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.107732_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-8722-6-79","article-title":"Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing","volume":"6","author":"Mesa","year":"2013","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2025.107732_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"issue":"26","key":"10.1016\/j.leukres.2025.107732_bib17","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.2174\/092986712803251511","article-title":"Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib","volume":"19","author":"Mascarenhas","year":"2012","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.leukres.2025.107732_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ehm.10.28","article-title":"JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms","volume":"3","author":"Oh","year":"2010","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107732_bib19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.leukres.2025.107732_bib20","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"2","key":"10.1016\/j.leukres.2025.107732_bib21","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/rheumatology\/keab024","article-title":"JAK1: Number one in the family; number one in inflammation?","volume":"60","author":"Spinelli","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.leukres.2025.107732_bib22","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib23","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.3390\/cancers12092446","article-title":"Anti-glucosylsphingosine autoimmunity, JAK2V617F-dependent interleukin-1\u03b2 and JAK2V617F-independent cytokines in myeloproliferative neoplasms","volume":"12","author":"Allain-Maillet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.leukres.2025.107732_bib24","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2025.107732_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.leukres.2025.107732_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.leukres.2025.107732_bib27","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","article-title":"Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107732_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173505","article-title":"Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"885","author":"Covington","year":"2020","journal-title":"Eur. J. Pharm."},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.leukres.2009.01.035","article-title":"The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis","volume":"33","author":"Mesa","year":"2009","journal-title":"Leuk. Res."},{"issue":"33","key":"10.1016\/j.leukres.2025.107732_bib30","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1\u20132","key":"10.1016\/j.leukres.2025.107732_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","article-title":"Immpact, Core outcome measures for chronic pain clinical trials: IMMPACT recommendations","volume":"113","author":"Dworkin","year":"2005","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.leukres.2025.107732_bib32","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00277-017-3194-4","article-title":"Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"97","author":"Kuykendall","year":"2018","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107732_bib33","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"issue":"25","key":"10.1016\/j.leukres.2025.107732_bib34","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"COMFORT-II Investigators, Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.107732_bib35","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2025.107732_bib36","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Comfort- I investigators, Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.leukres.2025.107732_bib37","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1177\/0091270011405663","article-title":"The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers","volume":"52","author":"Shi","year":"2012","journal-title":"J. Clin. Pharm."},{"issue":"12","key":"10.1016\/j.leukres.2025.107732_bib38","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/jcph.1484","article-title":"Effect of itraconazole or rifampin on itacitinib pharmacokinetics when administered orally in healthy subjects","volume":"59","author":"Barbour","year":"2019","journal-title":"J. Clin. Pharm."},{"issue":"2","key":"10.1016\/j.leukres.2025.107732_bib39","article-title":"Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions","volume":"34","author":"Umehara","year":"2019","journal-title":"Drug Metab. Pers. Ther."},{"issue":"8","key":"10.1016\/j.leukres.2025.107732_bib40","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1182\/bloodadvances.2019001043","article-title":"A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease","volume":"4","author":"Schroeder","year":"2020","journal-title":"Blood Adv."},{"issue":"7","key":"10.1016\/j.leukres.2025.107732_bib41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jcph.102","article-title":"Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF)","volume":"53","author":"Chen","year":"2013","journal-title":"J. Clin. Pharm."},{"issue":"7","key":"10.1016\/j.leukres.2025.107732_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.clml.2022.01.012","article-title":"A phase 1\/2 study of the oral janus kinase 1 inhibitors INCB052793 and itacitinib alone or in combination with standard therapies for advanced hematologic malignancies","volume":"22","author":"Zeidan","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.leukres.2025.107732_bib43","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s003300050145","article-title":"Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus","volume":"7","author":"Prassopoulos","year":"1997","journal-title":"Eur. Radiol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:15:47Z","timestamp":1753157747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262500092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":43,"alternative-id":["S014521262500092X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107732","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107732"}}